Helicobacter Pylori Infection and Frequency of Clarithromycin Resistance by qPCR
DOI:
https://doi.org/10.51985/JBUMDC202244Keywords:
Helicobacter pylori, triple therapy, quadruple therapy, qPCR–qualitative polymerase chain reaction, sequential therapy, ELISA (Enzyme-Linked Immunosorbent Assays)Abstract
Objective: Determine the frequency of Helicobacter pylori (H. pylori) infection in our population, the response to triplequadruple regimen and resistance to clarithromycin.
Study Design and Setting: Study design is case-series, Medicare Cardiac & General Hospital, Karachi- 2020-2021. All
patients (N=110) were selected from outpatient department (OPD) of the Jinnah Medical College Hospital (JMCH) and
Medicare Cardiac and General Hospital.
Methodology: Patients with nausea, abdominal pain, diarrhea and IgG positive were included, and ELISA was done for
detection of H. pylori infection.. IgG negative for H. pylori and having other gastrointestinal infections were excluded from
this study. Patients positive with infection were prescribed the initial triple /quadruple regimen (triple regimen therapy
including Proton pump inhibitor (PPI) 20 mg, Metronidazole 400mg, Amoxicillin 250 mg or Quadruple therapy by adding
Bismuth subsalicylate). In ten cases of relapse Sequential / Rescue therapy were continued after a gap of 6 weeks included
PPI 20 mg, metronidazole 400mg ciprofloxacin 200mg BD or Levofloxacin 400 mg OD. The qPCR was performed for
the detecting resistant to clarithromycin in patients with H. pylori IgG positive after therapy.
Result: During the follow-up, 60 (54%) cases were recovered from initial triple regimen, whereas 40(36%) cases recovered
quadruple therapy and remaining 10 (7%) had clarithromycin resistance and were prescribed sequential therapy replacing
clarithromycin by fluoroquinolones.
Conclusion: The study showed that majority of H. pylori infected patient in our population recovered from initial
triple/quadruple regimen. The alternate option with clarithromycin resistant was sequential and rescue therapy with high
eradication rate.
References
Fallone CA, Moss SF, Malfertheiner P. “Reconciliation of
recent Helicobacter pylori treatment guidelines in a time of
increasing resistance to antibiotics.” Gastroenterology. 2019
;157(1):44–53. DOI: 10.1053/j.gastro.2019.04.011
Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe
SE, Valasek MA. Review article: the global emergence of
Helicobacter pylori antibiotic resistance. Alimentary
Pharmacology and Therapeutics, 2016: 43(4):514–33. doi:
1111/apt.13497
Godersk, K., Agudo Pena, S., and Alarcon, T.;“Helicobacter
pylori treatment: antibiotics or probiotics”. Appl Microbiol
Biotechnol. 2018:102:1–7 DOI: 10.1007/s00253-017-8535-
Latif S, Akhter N, Amjed S, Jafar J, Saleem B, et.al. Efficacy
of standard triple therapy versus Levofloxacin based alternate
therapy against Helicobacter pylori infection. Journal Pakistan
Medical Association (JPMA); 2018: 68: 1295-1299.
Mehmood K, Awan AA, Muhammad N, Hasan F, Nadir A.
Helicobacter pylori prevalence and histopathological findings
in dyspeptic patients. Journal of Ayub Medical College
Abbottabad.; 2014: 26(2):182-5.
Hooi, JKY, Lai WY, Ng WK, Suen, MMY, Underwood FE,
Tanyingoh, D et al. Global Prevalence of Helicobacter pylori
Infection: Systematic Review and Meta-Analysis.
Gastroenterology .2017; 153: 420–429.
Plummer , M. , Franceschi, S , Vignat, J, Forman, D., Martel,
C, Global burden of gastric Cancer attributable to Helicobacter
pylori Int J Cancer. 2015; 136(2):487-90. DOI: 10.1002/
ijc.28999
Samy W., Elnemr GM, Issa LF and Sedik W. “Prevalence of
Helicobacter Pylori Infection and its Correlation with Complete
Blood Count Parameters in Adult Males at Taif City, Saudi
Arabia”. SAS J. Med. 2016: Volume-2; Issue-3, p-49-54.
Zamani M, Ebrahimtabar F, Zamani V, Miller WH, AlizadehNavaei R, et.al; Systematic review with metanalysis: worldwide
prevalence of Helicobacter pylori infection. Alimentary
Pharmacology & Therapeutics. 2018: 47(7): 868–76, DOI:
1111/apt.14561
Nakamura S, and Matsumoto T. “Helicobacter pylori and
gastric mucosa-associated lymphoid tissue lymphoma: recent
progress in pathogenesis and management.” World Journal
of Gastroenterology (WJG). 2013:7;19(45):8181-7, doi:
3748/wjg. v19.i45.8181.
Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS.
Amoxicillin or tetracycline in bismuth-containing quadruple
therapy as first-line treatment for Helicobacter pylori infection.
; Gut Microbes, 11 ; 5:1314-1323, DOI: 10.1080/ 1949
2020.1754118
Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, et.al.;
Noninvasive molecular analysis of Helicobacter pylori: is it
time for tailored first-line therapy? World Journal of
Gastroenterology. 2017: 23:2453–2458, doi: 10.3748/wjg.
v23.i14.2453
Rasheed F, Ahmad T, Bilal R.” Prevalence and risk factors
of Helicobacter pylori infection among Pakistani population.
Pakistan Journal of Medical Sciences.:2012: 28(4):661-665.
Kim SY, and Chung JW. “Best Helicobacter pylori Eradication
Strategy in the Era of Antibiotic Resistance. Antibiotics
(Basel).”; 2020: 23;9(8):436. doi: 10.3390/antibiotics9080436
Gasparetto M, Pescarin M, Guariso G. “Helicobacter pylori
eradication therapy: current availabilities.” ISRN
gastroenterology. 2012: Volume 2012, 8 doi:10.5402/ 2012/
Kageyama C, Sato M, Sakae H, Obayashi Y, Kawahara Y ,
et.al.; “Increase in antibiotic resistant Helicobacter pylori in
a University Hospital in Japan.” J of infection and drug
resistance. ; 2019: 12; 597-602. doi: 10.2147/IDR.S196452
Fasciana T, Di Carlo P, Jouini A, Di Giulio M.. “Helicobacter
pylori: infection and new perspective for the treatment.”
Canadian Journal of infectious diseases and Medical
Microbiology; 2019: 2 pages , doi.org/10.1155/2019/9431369.
Park JY, Shin T-S, Kim J-H, Yoon HJ, Kim BJ.et.al. “The
Prevalence of Multidrug Resistance of Helicobacter pylori
and Its Impact on Eradication in Korea from 2017 to 2019:
A Single-Center Study.” Antibiotics; 2020: 9(10), 646;
doi:10.3390/antibiotics9100646.
Hwang TJ, Kim N, Kim HB, Lee BH, Nam RH, et.al. “Change
in antibiotic resistance of Helicobacter pylori strains and the
effect of A2143G point mutation of 23S rRNA on the
eradication of H. pylori in a single center of Korea.” J. Clin.
Gastroenterol.; 2010: 44, 536–543. DOI: 10.1097/ MCG.
b013e3181d04592
Qureshi NN, Gallaher B, Schiller N.L “Evolution of amoxicillin
resistance of Helicobacter pylori in vitro: characterization of
resistance mechanisms.” Microb. Drug Resistance.; 2014:
(6):509–16. doi:10.1089/mdr.2014.0019.
Cao Z, Chen Q, Zhang W, Liang X, Liao J, et.al. “Fourteenday optimized levofloxacin-based therapy versus classical
quadruple therapy for Helicobacter pylori treatment failures:
a randomized clinical trial”. Scandinavian journal of
gastroenterology; 2015. 50(10):1185–90. doi:10.3109/ 0036-
.2015.1037345.
Gisbert JP, Romano M, Gravina AG, Solis-Munoz P, Bermejo
F, et al. “Helicobacter pylori second-line rescue therapy with
levofloxacin- and bismuth-containing quadruple therapy, after
failure of standard triple or non-bismuth quadruple
treatments.”Alimentary pharmacology & therapeutics.
:41(8):768–75, doi:10.1111/apt.13128.
Liou JM, Chen C-C, Lee Y-C, Chang C-Y, Wu J-Y, et.al.
“Systematic review with meta-analysis: 10- or 14-day
sequential therapy vs. 14-day triple therapy in the first line
treatment of Helicobacter pylori infection.” Alimentary
pharmacology & therapeutics.; 2016: 43(4):470–81.
doi:10.1111/apt.13495.
Wang B, Wang Y-H, Lv Z-F, Xiong H-F, Wang H, et.al.
“Review: efficacy and safety of hybrid therapy for Helicobacter
pylori infection: a systematic review and meta-analysis.
Helicobacter. 2015:20(2):79–88. doi:10.1111/hel.12180.
Zullo A, Fiorini G, Scaccianoce G, Portincasa P, De Francesco
V, et.al. “Sequential therapy for First-Line Helicobacter pylori
eradication: 10- or 14-Day Regimen?” Journal of
Gastrointestinal and Liver Diseases; 2019: Vol. 28 No 1: 11-
doi.org/10.15403/jgld.2014.1121.281.hpy
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Samia Perwaiz Khan, Rubina Ghani, Safia Izhar, Ajeet Kumar, Ambreen Irshad, Shaista Emad, Aemen Moeen, Ayesha Abbasi, Maham Sattar, Syed Sohaib Hasan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
